This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

You Can Help

Chandler R. Dawson, MD; Roy Beck, MD, PhD; Kirk R. Wilhelmus, MD; Elisabeth J. Cohen, MD; HEDS Group

Arch Ophthalmol. 1996;114(1):89-90.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THE TREATMENT of herpes simplex virus (HSV) infections of the eye has been controversial for many years. One unresolved issue involves the use of corticosteroids in the treatment of HSV stromal keratitis. A second issue relates to the use of the potent antiviral, acyclovir, which has been demonstrated to be effective in preventing recurrences of HSV genital infections.¹ Now the results of two placebo-controlled therapeutic trials have addressed these two issues in the management of herpes simplex eye disease.^2,3

TOPICAL CORTICOSTEROIDS FOR HSV STROMAL KERATITIS

To evaluate topical corticosteroids, nine clinical centers in the United States recruited 106 patients with active HSV stromal keratitis, no epithelial defect, and no steroid treatment for at least 10 days.² Forty-nine patients were randomized to treatment with placebo and 57 patients to topical prednisolone phosphate drops. In a standardized regimen, the prednisolone (and placebo) drops were progressively decreased over a 10-week . . . [Full Text PDF of this Article]

Author Affiliations
San Francisco, Calif; Tampa, Fla; Houston, Tex; Philadelphia, Pa

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?